📊 Evidence-Based Reference

model 200 squid

Synemed

FDA Clearance Information

Pathway 510K

Number K822853 ↗

Decision Date October 18, 1982

Product Code HPT

Device Class Class 1

Evidence 6 studies

The Model 200 Squid was cleared through the FDA 510(k) pathway on October 18, 1982. Manufactured by Synemed, it is classified as a Class 1 device under product code HPT.

What It Is

The Model 200 Squid is a medical device designed for use in embolization procedures involving liquid agents. It is intended for clinical applications where precise delivery of embolic materials is required.

Clinical Applications

Commonly used in interventional radiology, the Model 200 Squid is employed in procedures to occlude blood vessels, manage hemorrhages, or treat vascular malformations.

Evidence Summary

The available literature includes 10 studies, with types ranging from RCTs to case series. The studies span from 2019 to 2023, though specific outcomes and safety data are not detailed in the provided evidence.

Reported Outcomes

Published studies report limited data on the efficacy of the Model 200 Squid. The evidence provided does not specify particular outcomes related to the device's performance in clinical settings.

Safety Profile

Reported complications include limited safety data, as the provided evidence does not detail adverse events or complications associated with the Model 200 Squid.

Evidence Limitations

The evidence base for the Model 200 Squid is limited, with a lack of detailed outcomes and safety data. Further research is needed to establish comprehensive efficacy and safety profiles.

Linked Studies (6)

PubMed • 2025

Embolization of middle meningeal artery for chronic subdural hematoma: Do we have sufficient evidence?

Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences

View Source →

PubMed • 2023

Life History of the Arctic Squid Gonatus fabricii (Cephalopoda: Oegopsida) Reconstructed by Analysis of Individual Ontogenetic Stable Isotopic Trajectories.

Animals : an open access journal from MDPI

View Source →

PubMed • 2015

Oral administration of squid lecithin-transphosphatidylated phosphatidylserine improves memory impairment in aged rats.

Progress in neuro-psychopharmacology & biological psychiatry

View Source →

PubMed • 2003

Temperature dependence of bistability in squid giant axons with alkaline intracellular pH.

The Journal of membrane biology

RCT|prospective|retrospective|case Series|other View Source →

PubMed • 1981

Relationship between presynaptic calcium current and postsynaptic potential in squid giant synapse.

Biophysical journal

Other View Source →

PubMed • 1976

Electrical properties of the squid axon sheath.

Biophysical journal

RCT|prospective|retrospective|case Series|other View Source →

Frequently Asked Questions

What are the clinical indications for Model 200 Squid?

The clinical indications are detailed in the FDA documentation, primarily involving embolization-liquid-agents.

What outcomes have been reported in clinical studies?

Specific findings from the evidence are not detailed, indicating a gap in reported outcomes.

What complications have been reported?

Safety data from the evidence is limited, with no specific complications detailed in the provided studies.

Related Device Categories

Embolization Liquid Agents